Trial Profile
Expanded Access To MLN8237, For An Individual Patient With Adenocarcinoma Of The Prostate (CTMS# 16-0122)
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Alisertib (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Expanded access; Therapeutic Use
- 03 Jan 2017 New trial record